 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...102103104105106107108109110111112...132133» |
- | Xalkori (crizotinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=152, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- Herceptin (trastuzumab) / Roche, Zelboraf (vemurafenib) / Roche
Enrollment closed, P2 data, Enrollment change: SHIVA: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=742, Active, not recruiting, Sponsor: Institut Curie
Recruiting --> Active, not recruiting | N=1000 --> 742
- carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jul 12, 2016
P1/2, N=35, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting | N=1000 --> 742 N=53 --> 35 | Trial primary completion date: Jun 2016 --> Jun 2017
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients (clinicaltrials.gov) - Jul 12, 2016
P2, N=120, Active, not recruiting, Sponsor: Chinese Academy of Medical Sciences
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Enrollment change, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Jul 11, 2016
P2, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
N=53 --> 35 | Trial primary completion date: Jun 2016 --> Jun 2017 N=150 --> 700
- | Erleada (apalutamide) / J&J
Phase classification, Metastases: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate (clinicaltrials.gov) - Jul 7, 2016
P1b, N=58, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=150 --> 700 Phase classification: P1 --> P1b
- | everolimus / Generic mfg.
Trial completion, Metastases: Everolimus in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jul 4, 2016
P2, N=53, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P1 --> P1b Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Kineret (anakinra) / SOBI
Trial primary completion date, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Jun 29, 2016
P1, N=147, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2019
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Jun 28, 2016
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial primary completion date: Jun 2017 --> Jun 2019 Not yet recruiting --> Recruiting
- ||||| cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Enrollment closed, Enrollment change: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov) - Jun 25, 2016
P3, N=90, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=134 --> 90
- cyclophosphamide / Generic mfg., everolimus / Generic mfg.
New P2 trial, Post-transplantation: OCTET-Ever: Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (clinicaltrials.gov) - Jun 24, 2016
P2, N=20, Recruiting, Sponsor: University of Cologne
- | New P1/2 trial, PD(L)-1 Biomarker, Pan tumor: ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - Jun 24, 2016
P1/2, N=285, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- ||| Zykadia (ceritinib) / Novartis
Biomarker, Enrollment open, Combination therapy, Metastases: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 23, 2016
P1, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=134 --> 90 Not yet recruiting --> Recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jun 23, 2016
P3, N=735, Not yet recruiting, Sponsor: Eisai Inc.
- everolimus / Generic mfg.
New trial: Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (clinicaltrials.gov) - Jun 22, 2016
P=N/A, N=75, Active, not recruiting, Sponsor: Radboud University
- ||| Sutent (sunitinib) / Pfizer
Enrollment open, Real-world evidence, Real-world, Metastases: OPALINE : A Study Of Morbidity And Mortality At 2 Years (clinicaltrials.gov) - Jun 20, 2016
P=N/A, N=150, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Signifor (pasireotide) / Recordati
Trial completion, Enrollment change, Trial primary completion date, Metastases: RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma (clinicaltrials.gov) - Jun 19, 2016
P2, N=14, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=25 --> 14 | Trial primary completion date: Nov 2016 --> Jun 2016
- ||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Enrollment closed, Enrollment change: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (clinicaltrials.gov) - Jun 19, 2016
P3, N=130, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=25 --> 14 | Trial primary completion date: Nov 2016 --> Jun 2016 Recruiting --> Active, not recruiting | N=106 --> 130
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Jun 16, 2016
P1b/2, N=153, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | N=106 --> 130 Phase classification: P1/2 --> P1b/2
- || Trial primary completion date, Gene Expression Profile, IO biomarker, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=88, Active, not recruiting, Sponsor: Northwestern University
Phase classification: P1/2 --> P1b/2 Trial primary completion date: May 2016 --> May 2017
- | everolimus / Generic mfg., fulvestrant / Generic mfg., exemestane / Generic mfg.
Enrollment open, Trial initiation date, Metastases: FEVEX: Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer (clinicaltrials.gov) - Jun 15, 2016
P3, N=745, Recruiting, Sponsor: Consorzio Oncotech
Trial primary completion date: May 2016 --> May 2017 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Enrollment change, Combination therapy, Metastases: TRINITI-1: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (clinicaltrials.gov) - Jun 15, 2016
P1/2, N=51, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 Not yet recruiting --> Recruiting | N=40 --> 51
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Jun 13, 2016
P2, N=40, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting --> Recruiting | N=40 --> 51 Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Jun 10, 2016
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018 Suspended --> Active, not recruiting
- everolimus / Generic mfg.
Trial primary completion date: UNIRAD: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy (clinicaltrials.gov) - Jun 5, 2016
P3, N=1984, Recruiting, Sponsor: UNICANCER
Suspended --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jun 2021
- | everolimus / Generic mfg.
Enrollment change: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - May 26, 2016
P4, N=50, Recruiting, Sponsor: Radboud University
Trial primary completion date: Jan 2018 --> Jun 2021 N=75 --> 50
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial primary completion date: SORAVE - Sorafenib and Everolimus in Solid Tumors (clinicaltrials.gov) - May 25, 2016
P1, N=36, Completed, Sponsor: University of Cologne
N=75 --> 50 Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Feb 2014
- everolimus / Generic mfg.
Enrollment change, Trial primary completion date: Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) - May 25, 2016
P=N/A, N=25, Recruiting, Sponsor: Radboud University
Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Feb 2014 N=100 --> 25 | Trial primary completion date: Apr 2016 --> Aug 2016
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - May 25, 2016
P1, N=114, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=100 --> 25 | Trial primary completion date: Apr 2016 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Enrollment change, Trial primary completion date, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - May 24, 2016
P2, N=150, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 N=700 --> 150 | Trial primary completion date: Feb 2017 --> Feb 2019
- SNX-5422 / Esanex
Enrollment closed, Enrollment change: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (clinicaltrials.gov) - May 24, 2016
P1, N=19, Active, not recruiting, Sponsor: Esanex Inc.
N=700 --> 150 | Trial primary completion date: Feb 2017 --> Feb 2019 Recruiting --> Active, not recruiting | N=15 --> 19
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath (clinicaltrials.gov) - May 23, 2016
P4, N=50, Recruiting, Sponsor: University of Toledo Health Science Campus
Recruiting --> Active, not recruiting | N=15 --> 19 Trial primary completion date: Dec 2015 --> Jul 2018
- | everolimus / Generic mfg., nintedanib / Generic mfg.
Trial completion, Trial primary completion date: BARIS: BIBF 1120 and RAD001 in Solid Tumors - Phase I (clinicaltrials.gov) - May 21, 2016
P1, N=18, Completed, Sponsor: University of Cologne
Trial primary completion date: Dec 2015 --> Jul 2018 Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Oct 2014
- Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Enrollment closed, Epigenetic controller, Metastases: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) - May 19, 2016
P1, N=249, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: CATChEz: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - May 19, 2016
P2, N=70, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Feb 2017
- | everolimus / Generic mfg.
Trial termination, Monotherapy, Metastases: RAMSETE/CDE16: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (clinicaltrials.gov) - May 19, 2016
P2, N=73, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2016 --> Feb 2017 Active, not recruiting --> Terminated
- ||| Simulect (basiliximab) / Novartis
Clinical: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - May 14, 2016
P4, N=2024, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Phase classification, Trial termination: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (clinicaltrials.gov) - May 13, 2016
P2, N=9, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Phase classification: P4 --> P2 | Completed --> Terminated; Poor patients' accrual
- | prednisone / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: PredEver first: Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (clinicaltrials.gov) - May 13, 2016
P2a, N=38, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Phase classification: P4 --> P2 | Completed --> Terminated; Poor patients' accrual Recruiting --> Active, not recruiting | N=60 --> 38 | Trial primary completion date: Jan 2016 --> Jan 2017
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - May 13, 2016
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=60 --> 38 | Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014
- everolimus / Generic mfg.
Trial completion, Enrollment change: DCLNF1: Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T (clinicaltrials.gov) - May 13, 2016
P2, N=24, Completed, Sponsor: The University of Texas Health Science Center, Houston
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Recruiting --> Completed | N=20 --> 24
- | everolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Trial primary completion date: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder (clinicaltrials.gov) - May 10, 2016
P1/2, N=33, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed | N=20 --> 24 N=45 --> 33 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||| everolimus / Generic mfg., exemestane / Generic mfg.
Trial completion, Metastases: Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 6, 2016
P2, N=92, Completed, Sponsor: Novartis Pharmaceuticals
N=45 --> 33 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- everolimus / Generic mfg.
Enrollment change, Trial withdrawal: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - May 5, 2016
P2, N=0, Withdrawn, Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed N=25 --> 0 | Recruiting --> Withdrawn
- || Nulojix (belatacept) / BMS
Clinical: Regimen Optimization Study (clinicaltrials.gov) - May 4, 2016
P2, N=240, Recruiting, Sponsor: Bristol-Myers Squibb
N=25 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Sep 2017 --> Sep 2018
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date: AFINIVEST: The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (clinicaltrials.gov) - May 4, 2016
P3, N=53, Completed, Sponsor: Hopital Foch
Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2014
- polyTregs / National Institute of Allergy and Infectious Diseases
Enrollment open, IO biomarker: TASK: Treg Therapy in Subclinical Inflammation in Kidney Transplantation (clinicaltrials.gov) - May 4, 2016
P1/2, N=45, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- || cyclophosphamide / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer (clinicaltrials.gov) - May 3, 2016
P1/2, N=96, Recruiting, Sponsor: Hans J. van der Vliet, MD, PhD
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Jan 2017
- ||||| Opdivo (nivolumab) / BMS
Enrollment change, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) (clinicaltrials.gov) - May 3, 2016
P3, N=1054, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2016 --> Jan 2017 N=822 --> 1054
- everolimus / Generic mfg.
Trial primary completion date: EXIST-LT: Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus (clinicaltrials.gov) - May 2, 2016
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=822 --> 1054 Trial primary completion date: Jun 2026 --> Feb 2026